The estimated Net Worth of Jason S Fisherman is at least $2.41 Million dollars as of 14 November 2019. Jason Fisherman owns over 20,000 units of Exelixis Inc stock worth over $2,396,700 and over the last 21 years Jason sold EXEL stock worth over $16,418.
Jason has made over 12 trades of the Exelixis Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently Jason exercised 20,000 units of EXEL stock worth $65,600 on 14 November 2019.
The largest trade Jason's ever made was exercising 20,000 units of Exelixis Inc stock on 14 November 2019 worth over $65,600. On average, Jason trades about 2,709 units every 152 days since 2003. As of 14 November 2019 Jason still owns at least 90,000 units of Exelixis Inc stock.
You can see the complete history of Jason Fisherman stock trades at the bottom of the page.
Jason's mailing address filed with the SEC is C/O ACHILLION PHARMACEUTICALS, INC., 1777 SENTRY PARKWAY W, BLDG 14, STE 200, BLUE BELL, PA, 19422.
Over the last 23 years, insiders at Exelixis Inc have traded over $82,392,913 worth of Exelixis Inc stock and bought 1,847,609 units worth $19,175,184 . The most active insiders traders include Jean Francois Formela, Michael Morrissey, and Stelios Papadopoulos. On average, Exelixis Inc executives and independent directors trade stock every 12 days with the average trade being worth of $898,709. The most recent stock trade was executed by Jeffrey Hessekiel on 26 August 2024, trading 20,000 units of EXEL stock currently worth $488,200.
exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.
Exelixis Inc executives and other stock owners filed with the SEC include: